Asia Executives On The Move: Comings And Goings At BeiGene, Harbour BioMed, TLC, GC Pharma
Executive Summary
New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.
You may also be interested in...
Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
New Korea Commission Needs Status To Function As Control Tower: Industry
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.